Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes

Tim J. McDonald; Jane McEneny; Ewan R. Pearson; Gaya Thanabalasingham; Magdalena Szopa; Beverley M. Shields; Sian Ellard; Katharine R. Owen; Maciej T. Malecki; Andrew T. Hattersley; Ian S. Young

doi:10.1016/j.cca.2012.02.005

Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes

Tim J. McDonald
, Jane McEneny
, Ewan R. Pearson
, Gaya Thanabalasingham
, Magdalena Szopa
, Beverley M. Shields
, Sian Ellard
, Katharine R. Owen
, Maciej T. Malecki
, Andrew T. Hattersley
, Ian S. Young

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

Abstract

Introduction: The young-onset diabetes seen in HNF1A-MODY is often misdiagnosed as Type 2 diabetes. Type 2 diabetes, unlike HNF1A-MODY, is associated with insulin resistance and a characteristic dyslipidaemia. We aimed to compare the lipid profiles in HNF1A-MODY. Type 2 diabetes and control subjects and to determine if lipids can be used to aid the differential diagnosis of diabetes sub-type.

Methods: (1)) 14 subjects in each group (HNF1A-MODY. Type 2 diabetes and controls) were matched for gender and BMI. Fasting lipid profiles and HDL lipid constituents were compared in the 3 groups.(2)) HDL-cholesterol was assessed in a further 267 patients with HNF1A-MODY and 297 patients with a diagnosis of Type 2 diabetes to determine its discriminative value.

Results: (1)) In HNF1A-MODY subjects, plasma-triglycerides were lower (1.36 vs. 1.93 mmol/l, p = 0.07) and plasma-HDL-cholesterol was higher than in subjects with Type 2 diabetes (1.47 vs. 1.15 mmol/l, p = 0.0008), but was similar to controls. Furthermore, in the isolated HDL; HDL-phospholipid and HDL-cholesterol ester content were higher in HNF1A-MODY, than in Type 2 diabetes (1.59 vs. 1.33 mmol/L, p=0.04 and 1.10 vs. 0.83 mmol/L, p = 0.019, respectively), but were similar to controls (1.59 vs. 1.45 mmol/L, p = 0.35 and 1.10 vs. 1.21 mmol/L p = 0.19, respectively).(2)) A plasma-HDL-cholesterol >1.12 mmol/L was 75% sensitive and 64% specific (ROC AUC=0.76) at discriminating HNF1A-MODY from Type 2 diabetes.

Conclusion: The plasma-lipid profiles of HNF1A-MODY and the lipid constituents of HDL are similar to nondiabetic controls. However, HDL-cholesterol was higher in HNF1A-MODY than in Type 2 diabetes and could be used as a biomarker to aid in the identification of patients with HNF1A-MODY. (C) 2012 Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	927-932
Number of pages	6
Journal	Clinica Chimica Acta
Volume	413
Issue number	9-10
DOIs	https://doi.org/10.1016/j.cca.2012.02.005
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.cca.2012.02.005

Cite this

@article{d1c2c68bcba6454db0bad62980e1aa80,

title = "Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes",

abstract = "Introduction: The young-onset diabetes seen in HNF1A-MODY is often misdiagnosed as Type 2 diabetes. Type 2 diabetes, unlike HNF1A-MODY, is associated with insulin resistance and a characteristic dyslipidaemia. We aimed to compare the lipid profiles in HNF1A-MODY. Type 2 diabetes and control subjects and to determine if lipids can be used to aid the differential diagnosis of diabetes sub-type.Methods: (1)) 14 subjects in each group (HNF1A-MODY. Type 2 diabetes and controls) were matched for gender and BMI. Fasting lipid profiles and HDL lipid constituents were compared in the 3 groups.(2)) HDL-cholesterol was assessed in a further 267 patients with HNF1A-MODY and 297 patients with a diagnosis of Type 2 diabetes to determine its discriminative value.Results: (1)) In HNF1A-MODY subjects, plasma-triglycerides were lower (1.36 vs. 1.93 mmol/l, p = 0.07) and plasma-HDL-cholesterol was higher than in subjects with Type 2 diabetes (1.47 vs. 1.15 mmol/l, p = 0.0008), but was similar to controls. Furthermore, in the isolated HDL; HDL-phospholipid and HDL-cholesterol ester content were higher in HNF1A-MODY, than in Type 2 diabetes (1.59 vs. 1.33 mmol/L, p=0.04 and 1.10 vs. 0.83 mmol/L, p = 0.019, respectively), but were similar to controls (1.59 vs. 1.45 mmol/L, p = 0.35 and 1.10 vs. 1.21 mmol/L p = 0.19, respectively).(2)) A plasma-HDL-cholesterol >1.12 mmol/L was 75\% sensitive and 64\% specific (ROC AUC=0.76) at discriminating HNF1A-MODY from Type 2 diabetes.Conclusion: The plasma-lipid profiles of HNF1A-MODY and the lipid constituents of HDL are similar to nondiabetic controls. However, HDL-cholesterol was higher in HNF1A-MODY than in Type 2 diabetes and could be used as a biomarker to aid in the identification of patients with HNF1A-MODY. (C) 2012 Elsevier B.V. All rights reserved.",

author = "McDonald, \{Tim J.\} and Jane McEneny and Pearson, \{Ewan R.\} and Gaya Thanabalasingham and Magdalena Szopa and Shields, \{Beverley M.\} and Sian Ellard and Owen, \{Katharine R.\} and Malecki, \{Maciej T.\} and Hattersley, \{Andrew T.\} and Young, \{Ian S.\}",

year = "2012",

doi = "10.1016/j.cca.2012.02.005",

language = "English",

volume = "413",

pages = "927--932",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

number = "9-10",

}

TY - JOUR

T1 - Lipoprotein composition in HNF1A-MODY

T2 - differentiating between HNF1A-MODY and type 2 diabetes

AU - McDonald, Tim J.

AU - McEneny, Jane

AU - Pearson, Ewan R.

AU - Thanabalasingham, Gaya

AU - Szopa, Magdalena

AU - Shields, Beverley M.

AU - Ellard, Sian

AU - Owen, Katharine R.

AU - Malecki, Maciej T.

AU - Hattersley, Andrew T.

AU - Young, Ian S.

PY - 2012

Y1 - 2012

N2 - Introduction: The young-onset diabetes seen in HNF1A-MODY is often misdiagnosed as Type 2 diabetes. Type 2 diabetes, unlike HNF1A-MODY, is associated with insulin resistance and a characteristic dyslipidaemia. We aimed to compare the lipid profiles in HNF1A-MODY. Type 2 diabetes and control subjects and to determine if lipids can be used to aid the differential diagnosis of diabetes sub-type.Methods: (1)) 14 subjects in each group (HNF1A-MODY. Type 2 diabetes and controls) were matched for gender and BMI. Fasting lipid profiles and HDL lipid constituents were compared in the 3 groups.(2)) HDL-cholesterol was assessed in a further 267 patients with HNF1A-MODY and 297 patients with a diagnosis of Type 2 diabetes to determine its discriminative value.Results: (1)) In HNF1A-MODY subjects, plasma-triglycerides were lower (1.36 vs. 1.93 mmol/l, p = 0.07) and plasma-HDL-cholesterol was higher than in subjects with Type 2 diabetes (1.47 vs. 1.15 mmol/l, p = 0.0008), but was similar to controls. Furthermore, in the isolated HDL; HDL-phospholipid and HDL-cholesterol ester content were higher in HNF1A-MODY, than in Type 2 diabetes (1.59 vs. 1.33 mmol/L, p=0.04 and 1.10 vs. 0.83 mmol/L, p = 0.019, respectively), but were similar to controls (1.59 vs. 1.45 mmol/L, p = 0.35 and 1.10 vs. 1.21 mmol/L p = 0.19, respectively).(2)) A plasma-HDL-cholesterol >1.12 mmol/L was 75% sensitive and 64% specific (ROC AUC=0.76) at discriminating HNF1A-MODY from Type 2 diabetes.Conclusion: The plasma-lipid profiles of HNF1A-MODY and the lipid constituents of HDL are similar to nondiabetic controls. However, HDL-cholesterol was higher in HNF1A-MODY than in Type 2 diabetes and could be used as a biomarker to aid in the identification of patients with HNF1A-MODY. (C) 2012 Elsevier B.V. All rights reserved.

AB - Introduction: The young-onset diabetes seen in HNF1A-MODY is often misdiagnosed as Type 2 diabetes. Type 2 diabetes, unlike HNF1A-MODY, is associated with insulin resistance and a characteristic dyslipidaemia. We aimed to compare the lipid profiles in HNF1A-MODY. Type 2 diabetes and control subjects and to determine if lipids can be used to aid the differential diagnosis of diabetes sub-type.Methods: (1)) 14 subjects in each group (HNF1A-MODY. Type 2 diabetes and controls) were matched for gender and BMI. Fasting lipid profiles and HDL lipid constituents were compared in the 3 groups.(2)) HDL-cholesterol was assessed in a further 267 patients with HNF1A-MODY and 297 patients with a diagnosis of Type 2 diabetes to determine its discriminative value.Results: (1)) In HNF1A-MODY subjects, plasma-triglycerides were lower (1.36 vs. 1.93 mmol/l, p = 0.07) and plasma-HDL-cholesterol was higher than in subjects with Type 2 diabetes (1.47 vs. 1.15 mmol/l, p = 0.0008), but was similar to controls. Furthermore, in the isolated HDL; HDL-phospholipid and HDL-cholesterol ester content were higher in HNF1A-MODY, than in Type 2 diabetes (1.59 vs. 1.33 mmol/L, p=0.04 and 1.10 vs. 0.83 mmol/L, p = 0.019, respectively), but were similar to controls (1.59 vs. 1.45 mmol/L, p = 0.35 and 1.10 vs. 1.21 mmol/L p = 0.19, respectively).(2)) A plasma-HDL-cholesterol >1.12 mmol/L was 75% sensitive and 64% specific (ROC AUC=0.76) at discriminating HNF1A-MODY from Type 2 diabetes.Conclusion: The plasma-lipid profiles of HNF1A-MODY and the lipid constituents of HDL are similar to nondiabetic controls. However, HDL-cholesterol was higher in HNF1A-MODY than in Type 2 diabetes and could be used as a biomarker to aid in the identification of patients with HNF1A-MODY. (C) 2012 Elsevier B.V. All rights reserved.

U2 - 10.1016/j.cca.2012.02.005

DO - 10.1016/j.cca.2012.02.005

M3 - Article

SN - 0009-8981

VL - 413

SP - 927

EP - 932

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

IS - 9-10

ER -

Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this